Suneel Research Foundation

Organization Overview

Suneel Research Foundation is located in Buffalo, NY. The organization was established in 2003. According to its NTEE Classification (T03) the organization is classified as: Professional Societies & Associations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Suneel Research Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2021, Suneel Research Foundation generated $24.0k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (11.3%) each year. All expenses for the organization totaled $20.8k during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (10.7%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2021

Describe the Organization's Mission:

Part 3 - Line 1

THE FOUNDATION RAISES MONEY TO FOSTER AND ADVANCE MEDICAL AND SCIENTIFIC RESEARCH TO FIND A CURE FOR DUCHENNE'S MUSCULAR DYSTROPHY. IN ADDITION, THE FOUNDATION SEEKS TO PREVENT AND ALLEVIATE SUFFERING & PROMOTE EDUCATION & AWARENESS OF DUCHENNE'S MUSCULAR DYSTROPHY.

Describe the Organization's Program Activity:

Part 3 - Line 4a

THE FOUNDATION FUNDS RESEARCH ACTIVITIES TO FIND A CURE FOR DUCHENNE'S MUSCULAR DYSTROPHY (DMD). CURRENTLY THERE ARE A NUMBER OF CLINICAL TRIALS UNDERWAY FOR DRUGS DEVELOPED TO TREAT VARIOUS ASPECTS OF DMD. IN SEPTEMBER 2016, SAREPTA THERAPEUTICS, WON FDA APPROVAL FOR THE USE OF ITS DRUG EXONDYS 51 FOR THE TREATMENT OF DMD PATIENTS THAT HAVE A CONFIRMED MUTATION OF THE DYSTROPHIN GENE AMENABLE TO EXON 51 SKIPPING. IN DECEMBER 2019, SAREPTA, WON FDA APPROVAL FOR ITS NEW DRUG VYONDYS 53 FOR THE TREATMENT OF PATIENTS THAT HAVE A CONFIRMED MUTATION OF THE DYSTROPHIN GENE CONNECTED TO EXON 53 SKIPPING. BOTH TREATMENTS HELP APPROXIMATELY 21% OF THE PATIENTS AFFLICTED WITH DMD.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Neera Gulati MD
President
$0
Kenneth Manning ESQ
Vice President
$0
Thomas A Maher CPA
Treasurer
$0
Anita Ballow
Secretary
$0
David J Korzak
Director
$0
William Christ ESQ
Director
$0

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$23,300
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$23,300
Total Program Service Revenue$0
Investment income $717
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales $0
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $24,017

Grants Recieved

Over the last fiscal year, we have identified 1 grants that Suneel Research Foundation has recieved totaling $10,000.

Awarding OrganizationAmount
Schwab Charitable Fund

San Francisco, CA

PURPOSE: PUBLIC, SOCIETAL BENEFIT

$10,000
View Grant Recipient Profile

Create an account to unlock the data you need.

or